Ye, Jing Christine

Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 study.

Chari, A., Touzeau, C., Schinke, C., Minnema, M. C., Berdeja, J. G., Oriol, A., van de Donk, N. W. C. J., Rodríguez-Otero, P., Morillo, D., Martinez-Chamorro, C., et al. (2025) · The Lancet Haematology

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 116

The role of biomarkers in personalized immunotherapy

Sankar, K., Ye, J. C., Li, Z., Zheng, L., Song, W., & Hu-Lieskovan, S. (2022) · Biomarker Research

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 111

LINKER-MM1 study: Linvoseltamab (REGN5458) in patients with relapsed/refractory multiple myeloma.

Lee, H. C., Bumma, N., Richter, J. R., Dhodapkar, M. V., Hoffman, J. E., Suvannasankha, A., Zonder, J. A., Shah, M. R., Lentzsch, S., Maly, J. J., et al. (2023) · Journal of Clinical Oncology

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 57

Clinical management of patients with relapsed/refractory multiple myeloma treated with talquetamab

Chari, A., Krishnan, A., Rasche, L., Ye, J. C., Garfall, A., Popat, R., Lipe, B., Qin, X., Campagna, M., Masterson, T., et al. (2024) · Clinical Lymphoma Myeloma and Leukemia

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 53